Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: An overview

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 6, 2006, Pages 851-866

  Gazi, Irene F ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

C reactive protein; Ezetimibe; High density lipoprotein cholesterol; Sitosterolaemia; Statin; Triglyceride

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; COLESTYRAMINE; CYCLOSPORIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN K GROUP;

APHERESIS; AREA UNDER THE CURVE; AUTOIMMUNE HEPATITIS; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; GENE MUTATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LIVER FUNCTION TEST; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; MYOPATHY; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ANTILIPEMIC AGENTS; AZETIDINES; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 33751423668     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.6.851     Document Type: Review

References (167)

1. MIKHAILIDIS DP, WIERZBICKI AS, DASKALOPOULOU SS et al.: The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr. Med. Res. Opin. (2005) 21:959-969.
2. TOTH PP, DAVIDSON MH: Cholesterol absorption blockade with ezetimibe. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2005) 5:455-462.
3. ALTMANN SW, DAVIS HRJ, ZHU LJ et al.: Niemann-Pick C1 like protein is critical for intestinal cholesterol absorption. Science (2004) 303:1201-1204.
4. DAVIS HRJ, ZHU LJ, HOOS LM et al.: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. (2004) 279:33586-33592.
5. GARCIA-CALVO M, LISNOCK J, BULL HG et al.: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA (2005) 102:8132-8137.
6. SMART EJ, DE ROSE RA, FARBER SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA (2004) 101:3450-3455.
7. KRAMER W, GIRBIG F, CORSIERO D et al.: Aminopepridase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. (2005) 280:1306-1320.
8. DAVIDSON MH, TOTH PP: Comparative effects of lipid-lowering therapies. Prog. Cardiovasc. Dis. (2004) 47:73-104.
9. DAVIES GM, COOK JR, ERBEY J, ALEMAO E, VELTRI EP: Projected coronary heart disease risk benefit with ezetimibe. Atherosclerosis (2005) 179:375-378.
10. DAVIS HRJ, COMPTON DS, HOOS L, TETZLOFF G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. (2001) 21:2032-2038.
11. DASKALOPOULOU SS, MIKHAILIDIS DP: Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr. Med. Res. Opin. (2006) 22:511-528.
12. MIKHAILIDIS DP, WIERZBICKI AS: HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr. Med. Res. Opin. (2000) 16:139-146.
13. UK HDL-C CONSENSUS GROUP: Role of fibrates in reducing coronary risk: a UK consensus. Curr. Med. Res. Opin. (2004) 20:241-247.
14. TOTH PD: Clinician update: HDL and cardiovascular risk. Circulation (2004) 109:1809-1812.
15. SACKS FM for the Expert Group on HDL Cholesterol: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiol. (2002) 90:139-143.
16. CHAPMAN MJ, ASSMANN G, FRUCHART JC, SHEPHERD J, SIRTORI C; European Consensus Panel on HDL-C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr. Med. Res. Opin. (2004) 20:1253-1268.
17. RIZOS E, MIKHAILIDIS DP: Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc. Res. (2001) 52:199-207.
18. WIERZBICKI AS, MIKHAILIDIS DP: Beyond LDL-C-the importance of raising HDL-C. Curr. Med. Res. Opin. (2002) 18:36-44.
19. KOLOVOU GD, MIKHAILIDIS DP, ANAGNOSTOPOULOU KK, DASKALOPOULOU SS, COKKINOS DV: Tangier disease four decades of research: a reflection of the importance of HDL. Curr. Med. Chem. (2006) 13:771-782.
20. DUJOVNE CA, ETTINGER MP, MCNEER JF et al. for the Ezetimibe Study Group: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. (2002) 90:1092-1097.
21. SUDHOP T, LUTJOHANN D, KODAL A et al: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation (2002) 106:1943-1948.
22. SALEN G, VON BERGMANN K, LUTJOHANN D et al. and the Multicenter Sitosterolemia Study Group: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation (2004) 109:966-971.
23. BAYS HE, MOORE PB, DREBOHL MA et al. for the Ezetimibe Study Group: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two Phase II studies. Clin. Ther. (2001) 23:1209-1230.
24. JURADO J, SEIP R, THOMPSON PD: Effectiveness of ezetimibe in clinical practice. Am. J. Cardiol. (2004) 93:641-643.
25. LIBEROPOULOS EN, DASKALOPOULOU SS, MIKHAILIDIS DP: Management of high triglycerides: what non-specialists in lipids need to know. Hellenic J. Cardiol. (2005) 46:268-272.
26. KNOPP RH, GITTER H, TRUITT T et al. for the Ezetimibe Study Group: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. (2003) 24:729-741.
27. MILIONIS HJ, WINDER AF, MIKHAILIDIS DP: Lipoprotein (a) and stroke. J. Clin. Pathol. (2000) 53:487-496.
28. MILIONIS HJ, FILIPPATOS TD, LOUKAS T et al.: Serum lipoprorein (a) levels and apolipoprotein (a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis (2006) 187:170-176.
29. GANOTAKIS ES, GAZI IF, PAPADAKIS JA et al.: The relationship between circulating fibrinogen and lipoprotein (a) levels in patients with primary dyslipidemia. Clin. Appl. Thromb. Hemost. (2006) (In Press).
30. WALLDIUS G, JUNGNER I: Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets of lipid-modifying therapy. J. Intern. Med. (2004) 255:188-205.
31. GAZI I, TSIMIHODIMOS V, FILIPPATOS T et al.: Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 55:885-891.
32. GAZI I, LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF M: Metabolic syndrome: clinical features leading to therapeutic strategies. Vasc. Dis. Prevent. (2004) 1:253-263.
33. 2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. (2005) 51:2264-2273.
34. LAMARCHE B, TCHERNOF A, MOORJANI S et al.: Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results form the Quebec cardiovascular study. Circulation (1997) 95:69-75.
35. AL-SHAER MH: The effects of ezetimibe on the LDL-cholesterol particle number. Cardiovasc. Drugs Ther. (2004) 18:327-328.
36. GEISS HC, OTTO C, PARHOFER KG: Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients created by regular low-density lipoprotein apheresis and starins. Metabolism (2006) 55:599-604.
37. STAPRANS I, PAN XM, RAPP JH, MOSER AH, FEINGOLD KR: Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J. Lipid Res. (2006) (In Press).
38. LIBEROPOULOS EN, ATHYROS VG, ELISAF MS, MIKHAILIDIS DP: Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: where are we now aher the 'treating to new targets' (TNT) trial? Hellenic J. Cardiol. (2005) 46:161-164.
39. EUROASPIRE II STUDY GROUP: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EuroAspire II Euro Heart Survey Programme. Eur. Heart J. (2001) 22:554-572.
40. GAGNE C, BAYS HE, WEISS SR et al. for the Ezetimibe Study Group: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. (2002) 90:1084-1091.
41. BENNETT S, SAGER P, LIPKA L et al.: Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in men and women. J. Womens Health (Larchms) (2004) 13:1101-1107.
42. BALLANTYNE CM, BLAZING MA, KING TR, BRADY WE, PALMISANO J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. (2004) 93:1487-1494.
43. DAVIDSON MH, BALLANTYNE CM, KERZNER B et al. for the Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. (2004) 58:746-755.
44. PEARSON TA, DENKE MA, MCBRIDE PE et al.: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. (2005) 80:587-595.
45. PEARSON T, DENKE M, MCBRIDE P et al.: Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am. J. Geriatr. Pharmacother. (2005) 3:218-228.
46. LIPKA L, SAGER P, STRONY J et al. for the Ezetimibe Study Group: Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drug Aging (2004) 21:1025-1032.
47. PEARSON GJ, FRANCIS GA, ROMNEY JS et al.: The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Can. J. Cardiol. (2006) 22:939-945.
48. PATEL JV, HUGHES EA: Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg versus placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int. J. Clin. Pract. (2006) 60:914-921.
49. DAVIDSON MH, MCGARRY T, BETTIS R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 40:2125-2134.
50. BAYS HE, OSE L, FRASER N et al. for the Ezetimibe Study Group: A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. (2004) 26:1758-1773.
51. MASANA L, MATA P, GAGNE C et al. for the Ezetimibe Study Group: Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin. Ther. (2005) 27:174-184.
52. FELDMAN T, KOREN M, INSULL WJ et al.: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol. (2004) 93:1481-1486.
53. GOLDBERG AC, SAPRE A, LIU J, CAPESE R, MITCHEL YB for the Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. (2004) 79:620-629.
54. BALLANTYNE CM, ABATE N, YUAN Z, KING TR, PALMISANO J: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. (2005) 149:464-473.
55. FARNIER M, VOLPE M, MASSAAD R, DAVIES MJ, ALLEN C: Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol. (2005) 102:327-332.
56. BROHET C, BANAI S, ALINGS AM et al.: LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin. (2005) 21:571-578.
57. OSE L, SHAH A, DAVIES MJ et al.: Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr. Med. Res. Opin. (2006) 22:823-835.
58. RODNEY RA, SUGIMOTO D, WAGMAN B et al.: Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J. Natl. Med. Assoc. (2006) 98:772-778.
59. CATAPANO A, BRADY WE, KING TR, PALMISANO J: Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr. Med. Res. Opin. (2005) 21:1123-1130.
60. CRUZ-FERNANDEZ JM, BEDARIDA GV, ADGEY J et al.: Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int. J. Clin. Pract. (2005) 59:619-627.
61. BALLANTYNE CM, HOURI J, NOTARBARTOLO A et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 107:2409-2415.
62. STEIN E, STENDER S, MATA P et al.: Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. (2004) 148:447-455.
63. BALLANTYNE CM, LIPKA LJ, SAGER PT et al.: Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolemia. Int. J. Clin. Pract. (2004) 58:653-658.
64. BARRIOS V, AMABILE N, PAGANELLI F et al.: Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/ day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract. (2005) 59:1377-1386.
65. REYDERMAN L, KOSOGLOU T, CUTLER DL, MAXWELL SE, STATKEVICH P: The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Curr. Med. Res. Opin. (2005) 21:1171-1179.
66. MELANI L, MILLS R, HASSMAN D et al.: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. (2003) 24:717-728.
67. KOSOGLOU T, STATKEVICH P, YANG B et al.: Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr. Med. Res. Opin. (2004) 20:1185-1195.
68. KERZNER B, CORBELLI J, SHARP S et al.: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. (2003) 91:418-424.
69. KOSOGLOU T, STATKEVICH P, MEYER I et al.: Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr. Med. Res. Opin. (2004) 20:955-965.
70. KOSOGLOU T, STATKEVICH P, FRUCHART JC et al.: Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr. Med. Res. Opin. (2004) 20:1197-1207.
71. FARNIER M, FREEMAN MW, MACDONELL G et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. (2005) 26:897-905.
72. MCKENNEY J, FARNIER M, LO KW et al.: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. (2006) 47:1584-1587.
73. JELESOFF NE, BALLANTYNE CM, XYDAKIS AM et al.: Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr. Pract. (2006) 12:159-164.
74. XYDAKIS AM, GUYTON JR, CHIOU P et al.: Effectiveness and tolerability of ezetimibe add-on therapy to the bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol. (2004) 94:795-797.
75. ZEMA MJ: Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther. (2005) 12:306-310.
76. JAKULJ L, TRIP MD, SUDHOP T et al.: Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J. Lipid Res. (2005) 46:2692-2698.
77. SUDHOP T, GOTTWALD BM, VON BERGMANN K: Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism (2002) 51:1519-1521.
78. PEARSON TA, MENSAH GA, ALEXANDER RW et al.: Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation (2003) 107:499-511.
79. SAGER PT, MELANI L, LIPKA L et al.: Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol. (2003) 92:1414-1418.
80. SAGER PT, CAPESE R, LIPKA L et al.: Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis (2005) 179:361-367.
81. RIZOS E, KOSTOULA A, ELISAF M, MIKHAILIDIS DP: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology (2002) 53:273-277.
82. MILIONIS HJ, ELISAF MS, MIKHAILIDIS DP: Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr. Med. Res. Opin. (2000) 16:21-32.
83. ELISAF M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. (2002) 18:269-276.
84. RIZOS E, BAIRAKTARI ET, GANOTAKIS ES et al.: Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J. Cardiovasc. Pharmacol. Ther. (2002) 7:219-226.
85. KOSTOULA A, ELISAF M: Fibrates and C-reactive protein. Clin. Chim. Acta (2003) 328:197.
86. TSIMIHODIMOS V, KOSTOULA A, KAKAFIKA A et al.: Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J. Cardiovasc. Pharmacol. Ther. (2004) 9:27-33.
87. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism (2005) 54:1065-1074.
88. VAN HEYNINGEN C: Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann. Clin. Biochem. (2005) 42:402-404.
89. STOLK MF, BECX MC, KUYPERS KC, SELDENRIJK CA: Severe hepatic side effects of ezetimibe. Clin. Gastroenterol. Hepatol. (2006) 4:908-911.
90. KAKAFIKA A, LIAMIS G, ELISAF M, MIKHAILIDIS D: Effect of atorvastatin on serum creatinine levels. Curr. Med. Res. Opin. (2001) 17:230-231.
91. ATHYROS VG, PAPAGEORGIOU AA, ELISAF M, MIKHAILIDIS DP for the GREACE Study Collaborative Group: Statins and renal function in patients with diabetes mellitus. Curr. Med. Res. Opin. (2003) 19:615-617.
92. KAKAFIKA A, TSIMIHODIMOS V, ELISAF M: Effect of atorvastatin on serum uric acid levels. Atherosclerosis (2001) 158:255.
93. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J. Clin. Pathol. (2004) 57:728-734.
94. ATHYROS VG, ELISAF M, PAPAGEORGIOU AA et al.: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis. (2004) 43:589-599.
95. ELISAF M, MIKHAILIDIS DP: Statins and renal function. Angiology (2002) 53:493-502.
96. ALNAEB ME, YOUSSEF F, MIKHAILIDIS DP, HAMILTON G: Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology (2006) 57:65-71.
97. TSIMIHODIMOS V, KAKAFIKA A, ELISAF M: Fibrate treatment can increase serum creatinine levels. Nephrol. Dial. Transplant. (2001) 16:1301.
98. TSIMIHODIMOS V, BAIRAKTARI ET, ELISAF M: Fibrate-induced in serum urea and creatinine levels. Nephrol. Dial. Transplant. (2002) 17:682.
99. ACHIMASTOS A, LIBEROPOULOS E, NIKAS S et al.: The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr. Med. Res. Opin. (2002) 18:59-63.
100. TSIMIHODIMOS V, MILTIADOUS G, BAIRAKTARI ET, ELISAF M: Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin. Nephrol. (2002) 57:407-408.
101. TSIMIHODIMOS V, MILTIADOUS G, DASKALOPOULOU SS, MIKHAILIDIS DP, ELISAF MS: Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. (2005) 3:87-98.
102. LANDRAY M, BAIGENT C, LEAPER C et al.: The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am. J. Kidney Dis. (2006) 47:385-395.
103. HAVRANEK JM, WOLFSEN AR, WARNKE GA, PHILLIPS PS: Monotherapy with ezetimibe causing myopathy. Am. J. Med. (2006) 119:285-286.
104. SIMARD C, POIRIER P: Ezetimibe-associated myopathy in monotherapy and in combination with a hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can. J. Cardiol. (2006) 22:141-144.
105. PEREZ-CALVO J, CIVEIRA-MURILLO F, CABELLO A: Worsening myopathy associated with ezetimibe in a patient with McArdle disease. QJM (2005) 98:461-462.
106. PHILLIPS PS: Ezetimibe and statin-associated myopathy. Ann. Intern. Med. (2004) 141:649.
107. FUX R, MORIKE K, GUNDEL UF, HARTMANN R, GLEISER CH: Ezetimibe and statin-associated myopathy. Ann. Intern. Med. (2004) 140:671-672.
108. DAVIDSON MH, MACCUBBIN D, STEPANAVAGE M, STRONY J, MUSLINER T: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am. J. Cardiol. (2006) 97:223-228.
109. 10 in plasma: a randomised trial. Drug Saf. (2006) 29:703-712.
110. GONZALEZ-ORTIZ M, MARTINEZ-ABUNDIS E, KAM-RAMOS AM, HERNANDEZ-SALAZAR E, RAMOS-ZAVALA MG: Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc. Drugs Ther. (2006) 20:143-146.
111. DAVIGNON J, GANZ P: Role of endothelial dysfunction in atherosclerosis. Circulation (2004) 109(Suppl. 1):III27-III32.
112. TSIARA S, ELISAF M, MIKHAILIDIS DP: Early vascular benefits of statin therapy. Curr. Med. Res. Opin. (2003) 19:540-546.
113. BULUT D, HANEFELD C, BULUT-STREICH N et al.: Endothelial function in the forearm circulation of patients with the metabolic syndrome- Effect of different lipid-lowering regimens. Cardiology (2005) 104:176-180.
114. FICHTLSCHERER S, SCHMIDT-LUCKE C, BOJUNGA S et al.: Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur. Heart J. (2006) 27:1182-1190.
115. LANDMESSER U, BAHLMANN F, MUELLER M et al.: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 111:2356-2363.
116. ATHYROS VG, MIKHAILIDIS DP, DIDANGELOS TP et al.: Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. (2006) 22:873-883.
117. DAVIES JP, SCOTT C, OISHI K, LIAPIS A, IOANNOU YA: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. (2005) 280:12710-12720.
118. AHMED MH, SAAD RA, OSMAN MM: Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Expert Opin. Drug Saf. (2006) 5:487-488.
119. YAMAGISHI S, NAKAMURA K, MATSUI T, SATO T, TAKEUCHI M: Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med. Hypotheses (2006) 66:844-846.
120. VAN HEEK M, AUSTIN TM, FARLEY C et al.: Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes (2001) 50:1330-1335.
121. VAN HEEK M, FARLEY C, COMPTON DS, HOOS L, DAVIS HRJ: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol. (2001) 134:409-417.
122. VAN HEEK M, FARLEY C, COMPTON DS et al.: Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br. J. Pharmacol. (2003) 138:1459-1464.
123. REYDERMAN L, KOSOGLOU T, BOUTROS T, SEIBERLING M, STATKEVICH P: Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Curr. Med. Res. Opin. (2004) 20:1493-1500.
124. KOSOGLOU T, MEYER I, VELTRI EP et al.: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br. J. Clin. Pharmacol. (2002) 54:309-319.
125. GUSTAVSON LE, SCHWEITZER SM, BURT DA et al.: Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: a Phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin. Ther. (2006) 28:373-387.
126. REYDERMAN L, KOSOGLOU T, STATKEVICH P et al.: Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int. J. Clin. Pharmacol. Ther. (2004) 42:512-518.
127. KOSOGLOU T, STATKEVICH P, JOHNSON-LEVONAS AO et al.: Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmakinet. (2005) 44:467-494.
128. BERGMAN AJ, BURKE J, LARSON P et al.: Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J. Clin. Pharmacol. (2006) 46:328-336.
129. KOSHMAN SL, LALONDE LD, BURTON I, TYMCHAK WJ, PEARSON GJ: Supratherapeutic response to ezetimibe administered with cyclosporine. Ann. Pharmacother. (2005) 39:1561-1565.
130. BERGMAN AJ, BURKE J, LARSON P et al.: Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J. Clin. Pharmacol. (2006) 46:321-327.
131. ITO MK: Comment: Supratherapeutic response to ezetimibe administered with cyclosporine. Ann. Pharmacother. (2005) 39:2141.
132. WANG J, JOY T, MYMIN D, FROHLICH J, HEGELE RA. Phenotypic heterogeneity of sitosterolemia. J. Lipid Res. (2004) 45:2361-2367.
133. ASSMANN G, CULLEN P, ERBEY J et al.: Plasma sitosterol elevations are associated with an increased incidence of coronary events in men; results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr. Metab. Cardiovasc. Dis. (2006) 16:13-21.
134. MIETTINEN TA, GYLLING H, STRANDBERG TE, SARNA S: Finish 4S Investigators. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Br. Med. J. (1998) 316:1127-1130.
135. MIETTINEN TA, STRANDBERG TE, GYLLING H; Finish Investigators of the Scandinavian Simvastatin Survival Study Group: Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients. Relation to basal serum cholesterol. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1340-1346.
136. MIETTINEN TA, RAILO M, LEPANTALO M, GYLLING H: Plant sterols in serum and in atherosclerotic plaques of patients undergoing carotid endarterectomy. J. Am. Coll. Cardiol. (2005) 45:1794-1801.
137. SUDHOP T, LUTJOHANN D, VON BERGMANN K: Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol. Ther. (2005) 105:333-341.
138. VON BERGMANN K, SUDHOP T, LUTJOHANN D: Cholesterol and plant sterol absorption: recent insights. Am. J. Cardiol. (2005) 96(Suppl.):10D-14D.
139. SALEN G, STARC T, SISK CM, PATEL SB: Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology (2006) 130:1853-1857.
140. MOORJANI S, ROY M, TORRES A et al.: Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolemia. Lancet (1993) 341:1303-1306.
141. GAGNE C, GAUDET D, BRUCKERT E for the Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469-2475.
142. YAMAMOTO A, HARADA-SHIBA M, ENDO M et al.: The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis (2006) 186:126-131.
143. GEISS HC, OTTO C, HUND-WISSNER E, PARHOFER KG: Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis (2005) 180:107-112.
144. WIERZBICKI AS, DOHERTY E, LUMB PJ, CHIK G, CROOK MA: Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr. Med. Res. Opin. (2005) 21:333-338.
145. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: Prevalence of atherosclerotic vascular disease among patients with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr. Med. Res. Opin. (2004) 20:1691-1701.
146. LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF M: Diagnosis and management of the metabolic syndrome in obesity. Obes. Rev. (2005) 6:283-296.
147. LIBEROPOULOS EN, TSOULI S, MIKHAILIDIS DP, ELISAF MS: Preventing Type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr. Drug Targets (2006) 7:211-228.
148. SIMONS L, TONKON M, MASANA L et al.: Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin. (2004) 20:1437-1445.
149. GAUDIANI LM, LEWIN A, MENEGHINI L et al.: Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated Type 2 diabetic patients. Diabetes Obes. Metab. (2005) 7:88-97.
150. LANGONE AJ, CHUANG P: Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation (2006) 81:804-807.
151. PUTHENPARUMPIL JJ, KEOUGH-RYAN T, KIBERD M, LAWEN J, KIBERD BA: Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant. Proc. (2005) 37:1033-1035.
152. KOHNLE M, PIETRUCK F, KRIBBEN A et al.: Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am. J. Transplant. (2006) 6:205-208.
153. BUCHANAN C, SMITH L, CORBETT J, NELSON E, SHIHAB F: A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am. J. Transplant. (2006) 6:770-774.
154. PANICHI V, MANCA-RIZZA G, PAOLETTI S et al.: Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Biomed. Pharmacother. (2006) 60:249-252.
155. NESS GC, HOLLAND RC, LOPEZ D: Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption. Exp. Biol. Med. (Maywood) (2006) 231:559-565.
156. MIETTINEN TA, GYLLING H: Synthesis and absorption markets of cholesterol in serum and lipoproteins during a large dose of starin treatment. Eur. J. Clin. Invest. (2003) 33:976-982.
157. ZIAJKA PE, REIS M, KREUL S, KING H: Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am. J. Cardiol. (2004) 93:779-780.
158. MEYERS CD, MOON YSK, GHANEM H, WONG ND: Type of preexisting lipid therapy predicts LDL-C response to ezetimibe. Ann. Pharmacother. (2006) 40:818-823.
159. HEGELE RA, GUY J, BAN MR, WANG J: NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. (2005) 4:16.
160. SIMON JS, KARNOUB MC, DEVLIN DJ et al.: Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics (2005) 86:648-656.
161. LAMMERT F, WANG DQ: New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology (2005) 129:718-734.
162. WANG J, WILLIAMS CM, HEGELE RA: Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin. Genet. (2004) 67:175-177.
163. SEHAYEK E: Genetic regulation of cholesterol absorption and plasma plant sterol levels: commonalities and differences. J. Lipid Res. (2003) 44:2030-2038.
164. GYLLING H, MIETTINEN TA: Cholesterol absorption: influence of body weight and the role of plant sterols. Curr. Atheroscler. Rep. (2005) 7:466-471.
165. FELDMAN T, DAVIDSON M, SHAH A et al.: Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials. Clin. Ther. (2006) 28:849-859.
166. PEARSON TA, DENKE MA, MCBRIDE PE et al.: Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin. Proc. (2006) 81:1177-1185.
167. SMITH SC, ALLEN J, BLAIR SN et al.: AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 113:2363-2372.